New Guidelines Highlight Divalproex Sodium as an Effective Migraine Treatment

New Guidelines Highlight Divalproex Sodium as an Effective Migraine Treatment

neurology-articleThe latest news regarding divalproex sodium is exciting for patients who suffer from migraine headaches. A new set of guidelines were published in the April 24, 2012 issue of Neurology, and presented at the academy’s annual meeting in New Orleans April 21 to 28, 2013.  The new guidelines are composed of information from 29 studies that were published between 1999 and 2009. These studies describe effectual preventive treatments for migraine headaches. Among the vast array of prescription drugs evaluated, divalproex sodium was clearly shown to reduce the number of migraine attacks, as well as the severity of them for patients. The information that divalproex sodium, as well as several other anti-epileptic medications, can reduce the amount of migraine headaches by up to fifty percent was encouraging for patients, practitioners and research and development teams.

Divalproex Sodium CAS No: 76584-70-8Divalproex Sodium, CAS# 76584-70-8, is also known as the brand name Depakote ER. With the patent for Abbott’s pivotal treatment set to expire on December 18, 2018, researchers are taking another look at this powerhouse product. Divalproex sodium is approved to treat various types of seizure disorders. This medication helps with seizures by affecting the chemicals and nerves in the body that can cause the seizure activity. Divalproex Sodium is recommended as a stand-alone treatment or in combination with other anti-epileptic medications for adults. Children ages 10 and older are typically prescribed divalproex sodium to treat complex partial seizures. Patients with liver disease or a urea cycle disorder should not take this medication. Pancreatitis is a rare, but potential adverse effect of this medication. Common side effects include constipation, hair loss, tremors and upset stomach.

migraineThere are more than 37 million Americans who suffer from migraines and approximately 3.2 million Americans have chronic migraine, which is defined as migraine or tension-type headaches 15 or more days a month.  Statistics from the World Health Organization reveal that migraine headaches are responsible for at least 1% of the total U.S. medical disability burden.

LGM Pharma provides Divalproex Sodium for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service